Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC

Inclusion criteria

• 1) Men or women who are over 18 years old (including 18 years old) when signing the informed consent form;
• 2) Non-small cell lung cancer was confirmed by histology and could not be resected, and EGFR/ALK driver gene was confirmed negative by gene mutation examination;
• 3) At least one measurable lesion with imaging examination (according to RECIST1.1) is examined by spiral CT or MR, and the length and diameter of the lesion are ≥ 10 mm;
• 4) within 3 days before treatment, the score according to ECOG is 0 ~ 1;
• 5) Life expectancy ≥3 months;
• 6)The vital organs function well,
• 7)The subjects volunteered to join the study and signed the informed consent form, with good compliance and cooperation with the follow-up.

Exclusion criteria

• 1) Complicated with severe respiratory diseases: pulmonary fibrosis, active tuberculosis, etc.
• 2)Persons with mental disorder, blood system diseases, autoimmune diseases and serious primary diseases of heart, brain, liver and kidney;
• 3) Hemorrhagic events that require blood transfusion, invasive intervention or hospitalization occur within 3 months before the first administration, or there are bleeding symptoms and need intervention treatment (such as hemoptysis, hematuria and bloody stool), or high-risk factors with bleeding risk (such as tumor surrounding or invading important blood vessels, obvious necrosis or cavity around tumor, esophageal varices, etc.);
• 4) Thrombosis or embolic diseases, abnormal blood coagulation function and bleeding tendency;
• 5) Known or suspected to be allergic to the study drug and its auxiliary materials;
• 6) The baseline pregnancy test of pregnant and lactating women or fertile women is positive.
• 7) According to the researcher's judgment, the subjects have other factors that may lead to the forced termination of this study.